David Morgan is a Professor in the Department of Translational Neuroscience. He received his training at Northwestern University. His doctoral research at Northwestern University was with Aryeh Routtenberg, where they investigated the neurochemistry of memory, resulting in the publication of part of his dissertation in Science. Dr. Morgan’s postdoctoral studies addressed aging-related changes in rodent and human brains in the laboratory of Caleb “Tuck” Finch. Morgan became a faculty member at the University of Southern California in 1986 where his research projects focused on astrocytes and microglia in aged brain, including Alzheimer's tissues. After moving to South Florida in 1992, Morgan participated with John Hardy and Karen Duff in developing a transgenic mouse model of Alzheimer's disease (APP+PS1). He has developed methods to measure the damage that occurs in the brains of these mice and studied how this damage causes memory deficits in the mice. Morgan was the first to show that immunotherapy against the amyloid peptide rescued the memory deficits in APP mouse models of amyloid deposition.

Dr. Morgan has over 200 peer-reviewed publications; his H factor is 57. He has participated in 20 NIH-funded research grants totaling over 80 grant-years of research support as Principal investigator or Co-Investigator over the last 25 years.  His research program has received $16 million in support from multiple agencies. In addition to his research activities, Morgan has consulted with major pharmaceutical companies and small biotechnology companies regarding developing therapeutics for Alzheimer's disease. He has also advised capital investment organizations regarding the most promising therapeutic approaches to curing Alzheimer’s disease. Morgan served 6 years on the Program Committee for the Alzheimer's Association International Conference, the last 3 years as Chairperson.

Michigan State University Translational Neuroscience Profile